FK 866

Product Description

FK 866 is a non-competitive and high-affinity inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, PBEF1) (K_i = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC₅₀ ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by Etoposide (Cat. No. 1226) and Cisplatin (Cat. No. 2251).

Solubility

Preparing Stock Solutions for FK 866

The following data is based on the product molecular weight 391.51

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.55 mL	12.77 mL	25.54 mL
5 mM	0.51 mL	2.55 mL	5.11 mL
10 mM	0.26 mL	1.28 mL	2.55 mL
50 mM	0.05 mL	0.26 mL	0.51 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Travelli Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etop. or cisp. in neuroblastoma cells. J.Pharmacol.Exp.Ther. 2011 PMID: 21685314
• Galli Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. Chem.Med.Chem. 2008 PMID: 18247435
• Hasmann FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003 PMID: 14612543